Management of multimodal treatment of kidney cancer
DOI:
https://doi.org/10.52692/1857-0011.2023.1-75.26Keywords:
renal cancer, management, multimodal treatmentAbstract
Introduction. Renal cancer is a frequent tumor of the urinary system and occupies about 3% of the structure of oncological morbidity in adults. It has a significant worldwide morbidity - of about 200 thousand and a mortality of about 100 thousand annually. These trends are also characteristic of European and Romanian countries. The aim of the paper – is to carry out an analysis of the treatment management, including multimodality, of kidney cancer. Material and methods. To highlight the methods of multimodal treatment of kidney cancer. Bibliographic sources and clinical cases from the European and Eurasian literature, North America, Romania, the Republic of Moldova, and 256 records of kidney cancer patients undergoing specialized oncological treatments were analyzed. Conclusions. The multimodal treatment of renal cancer includes – surgical method, oncological method – chemotherapy, radiotherapy, biological and genomic treatment – personalized in perspective.
References
Sinescu I, Gluk G., Hîrza M., (2006, Bucureşti ) Urologie Oncologică, p. 7-72.
Birkhauser; Kroeger, Pantuck (2013). “Etiology of Renal Cell Carcinoma: Incidence, Demographics, and Environmental Factors”. Renal Cell Carcinoma Clinical Management. Humana Pr Inc. pp. 3–22. ISBN 978-162703-061-8.
Cohen, Herbert T.; McGovern, Francis J. (8 December 2005). “Renal-Cell Carcinoma”. New England Journal of Medicine 353 (23): 2477–2490. 10.1056/NEJMra043172.PMID 16339096.
Häggström, Christel; Rapp, Kilian; Stocks, Tanja; Manjer, Jonas; Bjørge, Tone; Ulmer, Hanno; Engeland, Anders; Almqvist, Martin et al. (2013). “Metabolic Factors Associated with Risk of Renal Cell Carcinoma”. In Miller, Todd W. PLoS ONE 8 (2):
Kim, Hyung L.; Belldegrun, Arie S.; Freitas, Danielo G.; Bui, Matthew H.T.; Han, Ken-Ryu; Dorey, Frederick J.; Figlin, Robert A. (1 November 2003). “Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis”. The Journal of Urology 170 (5): 1742–1746.
Lane (2013). “Prognostic Factors for Localised Renal Cell Carcinoma”. Renal Cell Carcinoma Clinical Management. Humana Pr Inc. pp. 83–102. ISBN 978-162703-061-8.
Ljungberg, Börje; Campbell, Steven C.; Cho, Han Yong; Jacqmin, Didier; Lee, Jung Eun; Weikert, Steffen; Kiemeney, Lambertus A. (2011). “The Epidemiology of Renal Cell Carcinoma”. European Urology 60(4): 615–21.
Metz; Davis (2013). “Palliative and Supportive Care for Renal Cancer”. Renal Cell Carcinoma Clinical Management. Humana Pr Inc. pp. 339–348. ISBN 978-162703-061-8.
Motzer, Robert J.; Bander, Neil H.; Nanus, David M. (19 September 1996). “Renal-Cell Carcinoma”. New England Journal of Medicine 335 (12): 865–875.
Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH (February 2008). “[Guideline ‘Renal cell carcinoma’]”. Ned Tijdschr Geneeskd (in Dutch; Flemish) 152(7): 376–80.
Ramana, Jayashree (2012). “RCDB: Renal Cancer Gene Database”. BMC Research Notes 5 (1).
Rini BI, Rathmell WK, Godley P (May 2008). “Renal cell carcinoma”. Curr Opin Oncol 20 (3): 300–6.
Singer, Eric A.; Gupta, Gopal N.; Marchalik, Daniel; Srinivasan, Ramaprasad (2013). “Evolving therapeutic targets in renal cell carcinoma”. Current Opinion in Oncology: 1.
Pocket Guidelines (2009 edition), European Association of Urology, p. 46-58.
Andrei Anghel, Ioan Ovidiu Sirbu, Catalin Marian, Liviu Tamas, Marilena Motoc. Introducere in terapia genica (2002) 123 pag. Editura Mirton, Timisoara, ISBN 973–585–839-8.
Nomura T, Yasuda K, Yamada T, Okamoto S, Mahato RI, Watanabe Y, Takakura Y, Hashida M. Gene expression and antitumor effects following direct interferon (IFN)-gamma gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther. 1999 Jan;6(1):121-9. doi: 10.1038/sj.gt.3300792
Downloads
Published
License
Copyright (c) 2023 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
